The transactions highlight Broadwood Partners' continued confidence in STAAR Surgical (NASDAQ:STAA), a company known for its ...

STAAR Surgical (NASDAQ:STAA) rose 6.5% amid some takeover speculation. The maker of implantable lenses is said to have been ...

Stifel Nicolaus analyst Thomas Stephan has maintained their bullish stance on STAA stock, giving a Buy rating on January 7.Stay Ahead of the ...

On January 17, BROADWOOD PARTNERS LP, 10% Owner at Staar Surgical STAA executed a significant insider buy, as disclosed in the latest SEC filing.

LAKE FOREST, Calif., January 13, 2025--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision ...

BTIG lowered the firm’s price target on Staar Surgical (STAA) to $39 from $49 and keeps a Buy rating on the shares as part of a broader research note updating the firm’s models on Medical ...

BTIG analyst Ryan Zimmerman maintained a Buy rating on Staar Surgical (STAA – Research Report) today and set a price target of $39.00. The ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

The transactions highlight Broadwood Partners' continued confidence in STAAR Surgical (NASDAQ:STAA), a company known for its ophthalmic goods. Neal C. Bradsher, President of Broadwood Capital ...

STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The firm offers implantable lenses for the eye and accessory delivery systems.